Filing Flows › Health Care › Yarrow Bioscience (YARW)
Yarrow Bioscience (YARW) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Yarrow Bioscience (YARW) Q2 2026 earnings results →
Q2 2026 Revenue up 41% year over year to $97K
Yarrow Bioscience made $97K in Q2 2026 (+41% Y/Y). Operating margin n/m, net loss $3.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $97K in Q2 2026, up 41% year over year and up 13% from the previous quarter.
Operating costs exceeded revenue by $3.1M, an operating margin of -3197.9%. Total costs fell 58% while revenue rose 41%. The quarter ended with a net loss of $3.0M, narrower than the previous quarter's $3.6M loss.
Operating cash flow was −$2.0M. Non-cash charges added back $6K of depreciation and amortization and $436K of share-based compensation. Working capital and other items added $573K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $97K | +41% | n/m | −$3.0M | −$2.0M |
| Q1 2026 | 10-Q | May 15, 2026 | $86K | -57% | n/m | −$3.6M | −$4.1M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $69K | -65% | n/m | −$5.8M | −$10.8M |
| Q1 2025 | 10-Q | May 8, 2025 | $202K | +106% | n/m | −$8.6M | −$11.5M |
| Q4 2024 | 10-K | Mar 6, 2025 | $84K | +10% | n/m | −$12.0M | −$9.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Yarrow Bioscience
We are a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat inflammatory and immune-mediated conditions with high unmet need. We have exclusive worldwide rights to research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (“BET”) inhibitors for the treatment of any disease, disorder or condition in humans, which we licensed from Tay Therapeutics Ltd., formerly known as In4Derm Ltd ("Tay"). BET proteins are epigenetic enablers of transcription that regulate the expression of specific genes. Each BET protein consists of two bromodomains (“BD1” and “BD2”) and one end terminal (“ET”) domain.
In its own words, from its 10-K, filed Feb 27, 2026.
Yarrow Bioscience against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +41% against the peers' median +10%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| YARW Yarrow Bioscience | Q2 2026 | $97K | +41% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Yarrow Bioscience 10-Q on SEC EDGAR · CIK 1566044 · Pharmaceutical Preparations
More on YARW
History
Every quarter: Q2 2026 results · Q1 2026 results · Q2 2025 results · Q1 2025 results · Q4 2024 results